OV329

About Ovid Therapeutics

Ovid Therapeutics is a New York-based biotech dedicated to conquering rare neurological diseases through courageous science. Founded in 2014, the company has evolved its pipeline to focus on next-generation mechanisms for treatment-resistant seizures and neurodevelopmental disorders, including its lead GABA-AT inhibitor OV329 and KCC2 activator platform. While its former lead asset, soticlestat, is partnered with Takeda, Ovid is now advancing a wholly-owned, precision-focused pipeline for high-need patient communities with significant unmet medical need.

Therapeutic Areas